Regenerative Therapies for Diabetic Microangiopathy
Table 3
Role of gene transfer in the treatment of diabetic microangiopathy. Gene transfer promotes endothelial cell proliferation, migration, and blood vessel formation. VEGF: vascular endothelial growth factor; FGF: fibroblast growth factor; HGF: hepatocyte growth factor; HIF-1α: hypoxia inducible factor-1α.
Study
Year
Identifier
Site
Status/recruited pts
VEGF
Vegf gene transfer for critical limb ischemia
2010
NCT00056290
Steward St. Elizabeth's Medical Center of Boston
Completed
VEGF gene transfer for diabetic neuropathy
2010
NCT00056290
Steward St. Elizabeth's Medical Center of Boston
Completed
Angiogenesis using VEGF-A165/bFGF plasmid delivered percutaneously in no-option CAD patients; a controlled trial (VIF-CAD)
2009
NCT00620217
Institute of Cardiology, Warsaw, Poland
Completed
FGF
Efficacy and safety study of NV1FGF in patients with severe peripheral artery occlusive disease (TALISMAN202)
2010
NCT00798005
Sanofi-Aventis
Completed
Efficacy and safety of XRP0038/NV1FGF in critical limb ischemia patients with skin lesions (TAMARIS)
2010
NCT00566657
Sanofi-Aventis
This study is ongoing, but not recruiting participants
HGF
Study of hepatocyte growth factor (HGF) via plasmid vector to improve perfusion in critical limb ischemia patients with peripheral ischemic ulcers
2011
NCT00189540
AnGes
This study has been completed
HIF
Safety and efficacy study of Ad2/Hypoxia inducible factor-1α (HIF-1α)/VP16 gene transfer in patients with intermittent claudication (WALK)